| Name | Title | Contact Details |
|---|
Guardian Pharmacy Services, headquartered in Atlanta, Georgia, is the nation’s third largest institutional pharmacy company and one of the fastest growing privately held companies in the state of Georgia. Founded in 2004, Guardian and its partner pharmacies focus on providing exceptional client service and patient care to long-term care customers in assisted living communities, skilled nursing facilities, hospice and behavioral health group homes. Guardian Pharmacy Services` business model allows partner pharmacies to operate as independent local businesses tailoring their services to the needs of customers in their respective markets. We take our responsibility to our customers and their residents very seriously, and always strive to make sure that every prescription we fill and every service we execute receives our utmost care and attention. In the end, customers are the winners as pharmacies devote more attention to them while still meeting the many demands of any business. Guardian is 100% committed to fostering a sustainable business driven by our core values, conducting business according to the Golden Rule; treating each other, our customers and residents fairly and honestly.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company`s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
Triax Pharmaceuticals is a Cranford, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LeafLine Labs was founded by practicing physicians who see the unnecessary suffering patients endure every day. We are, first and foremost, caregivers who exist to give our patients the quality of life they deserve.
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir`s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.